focal adhesion kinase 1 (FAK 1), paxillin, integrins, protein kinase Cδ (PKCδ), protein kinase Cε (PKCε), and STAT3, have been demonstrated, which implies that IL-32 may participate in inflammatory responses as an intracellular mediator (7) (8) (9) .
CCAAT/enhancer-binding protein (C/EBP) family of transcription factors are known to play important roles in cell proliferation and differentiation. The C/EBP family comprises 6 members: C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, C/EBPε, and C/EBPζ. Each member, except C/EBPζ, which lacks a canonical basic region, contains a similar basic region and leucine zipper sequence at its C-terminus that mediate DNA binding and dimerization, respectively (10-11). C/EBPα dimerizes with other members of the C/EBP family or with itself (12) , and interacts with other proteins such as TFIIB, TBP, Rb, p300/CBP, p21, and members of the SWI/SNF complex (13) (14) (15) (16) (17) . C/EBPα is known to upregulate the expression of granulocytic lineage-specific genes (18) (19) (20) (21) , both directly and synergistically with other key genessuch as CBF complex genes and PU.1 in myeloid development. C/EBPα also represses E2F-regulated genes by direct interaction with E2F, which induces cell cycle arrest (19, 22) .
It has also been shown that C/EBPα is regulated by phosphorylation and SUMOylation (SUMO = Small Ubiquitin-like Modifier) (23) (24) (25) . Phosphorylation of T222 and T226 on C/EBPα by glycogen synthase kinase 3(GSK3) causes profound conformational changes, which induce adipogenesis (25). C/EBPα phosphorylation on S21 by extracellular signalregulated kinase 1/2 (ERK1/2) inhibits granulopoiesis. Phosphorylation of C/EBPα S21 induces conformational changes (26). An oncogenic FLT3 kinase also inhibits the transcriptional activity of C/EBPα by phosphorylating S21 (27). We previously reported that IL-32β promotes IL-10 production in myeloid cells. In this study, we further verified our results and demonstrated an intracellular mediatory role of IL-32β for IL-10 production by showing that IL-32β promoted IL-10 production in a PKCδ-dependent way, where it mediated the phosphorylation of C/EBPα S21 by PKCδ. The phosphorylation of C/EBPα S21 suppressed its inhibitory role in IL-10 induction. Our data suggest that IL-32β may function as an intracellular regulator of inflammatory response as well as an inducer of inflammation.
Experimental procedures
Reagents and cell culture The human promyelomonocytic U937 cell line was grown in RPMI 1640 (WelGENE, Daegu, Korea) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum (Hyclone, Logan, UT). Human embryonic kidney 293 (HEK293) and lung carcinoma A549 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal bovine serum (10 %) and antibiotics. Phorbol 12-myristate 13-acetate (PMA), lipopolysaccharide (LPS), and polyinosinic:polycytidylic acid (poly[I:C]) were purchased from Sigma (St. Louis, MO). MAPK inhibitor (PD98059) and PKCδ inhibitor (rottlerin) and classical PKC inhibitor (Gӧ6976) were purchased from Calbiochem (San Diego, CA).
Measurement of IL-10 expression levels and enzyme-linked immunosorbent assay (ELISA)
IL-10 mRNA expression was detected by reverse transcription-polymerase chain reaction (RT-PCR) of total RNAs extracted from U937 cells after the various treatments with 10 nM of PMA, 1 μg/ml of (LPS), or 10 μg/ml of poly(I:C) for 24 h. U937 cells were also treated with increasing amounts of the PKCδ-specific inhibitor rottlerin for 24 h. The culture media were collected for ELISA. The IL-10 primer set used for PCR was as follows: sense 5′-AACCTGCCTAACATGCTTCGA-3′, antisense 5′-CTCATGGCTTTGTAGATGCCT-3′. Human IL-10, TNFα, and IL-8 ELISAs were performed using ELISA kits from R&D systems( Minneapolis, MN). Immunofluorescence analyses For immunofluorescence staining, U937 cells were treated with 50 nM of PMA or 1 μg/mL of LPS for 40 min; thereafter, 1 × 10 5 cells were transferred into 1.5-mL microfuge tube. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 20 min. After blocking with 1% bovine serum albumin (BSA) for 30 min, KU32-52 antibody to IL-32 (1:200) was incubated for 1 h. Fluorescein isothiocyanate (FITC)-conjugated anti-mouse secondary antibody (1:500) was used for staining. 4′,6-Diamidino-2-phenylindole (DAPI) was used for nuclei staining. Fluorescence images were obtained using a Zeiss LSM5 confocal microscope with Plan-Apochromat 63 × /1.4 Oil DIC objectives. Construction of expression vectors IL-32β cDNA was subcloned into pcDNA3.1+ 6 × myc vector by using EcoRІ and XhoІ. cDNAs for PKCα, PKCδ, PKCε, and PKCθ were subcloned into the pcDNA3.1+ 5 × flag vector by using EcoRІ and XhoІ (7) . Human intronless C/EBPα gene was PCR-amplified from THP-1 genomic DNA by using 2 overlapping primer sets to obtain entire cDNA; PCR was then conducted again using the 2 PCR fragment as templates. The primers sets were as follows: forward (F) 5′-GAATTCATGGAGTCGGCCGACTTCTAC-3′, reverse (R) 5′-CTCGAGTCACGCGCAGTT-GCCCATGGC-3′, forward 2 (F2) 5′-AGATCT-CGCACTGCGGCCAGACCACCA-3′, reverse 2 (R2) 5′-AGATCTGGAACTGCAGGTGCGG-GGCGG-3′. The entire amplified gene was sequenced and cloned into pCS3MT 6×myc vector using EcoRI and XhoI. A mutant C/EBPα at serine 21 to glycine (S21G) was generated by site-directed mutagenesis. The primer set for mutagenesis was as follows: forward 5′-AGCAGCCACCTGCAGGGCCCCCCGCAC-3′, reverse 5′-GGGCGCGTGCGGGGGGCCC-TGCAGGTG-3′. C/EBPα S21G was subcloned into 6 × myc pCS3MT vector and confirmed by sequencing. The deletion mutants of C/EBPα and IL-32β were generated by PCR and the PCR products were cloned into the pCS3MT 6×myc vector. Electroporation U937 promyelomonocytic cells were transfected with 1.5 μg of IL-32 siRNA or non-targeting siRNA using a Neon TM transfection system (Invitrogen, Carlsbad, CA). PKCδ siRNA 2 μg was transfected in the same way. PKCδ and IL-32 siRNA and non-targeting siRNA were purchased from Dharmacon (Lafayette, CO). The transfected cells were incubated overnight, and 10 nM PMA was then applied for the indicated time, after which cell lysates were prepared for western blotting. Western blotting and immunoprecipitation HEK293 cells were co-transfected with pcDNA3.1+ 6 × myc-IL-32β and pcDNA3.1+ 5 × flag-PKCs (PKCα, PKCδ, PKCε, and PKCθ). The different combinations of IL-32β, PKCδ, C/EBPα, and mutant C/EBPα S21G were cotransfected into HEK293. After overnight incubation, cells were treated with 10 μM of rottlerin or 10 μM of PD98059 for 1 h for the inhibitor-treated samples. PMA 20 nM was treated for a further 90 min, and then lysed in 50 mM HEPES, pH 7.5; 150 mM NaCl; 5% glycerol; 20 mM β-glycerophosphate; 1% NP-40; 0.5% TX-100; and 1 mM EDTA. Western blotting was performed using the myc tag antibody (Millipore-Upstate, Bedford, MA), pC/EBPα (serine 21) antibody (Cell signaling, Danvers, MA), and C/EBPα antibody (Santa Cruz). U937 cells were lysed after PMA treatment for the indicated time. Treatment with inhibitors was performed 1 h before PMA treatment. The optical density of the bands was measured by using Image Studio Lite Software after scanning the blots (LI-COR Biosciences, Lincoln, NE). For immunoprecipitation, cell lysates were mixed with 1 μg of myc antibody, 3 μg of C/EBPα antibody, or 3 ug of goat polyclonal IL-32 antibody (R&D systems) for 1 h, respectively, and then pulled down using 35 μl of protein G agarose bead (KPL, Gaithersburg, MD). IL-10 reporter plasmid and luciferase assay IL-10 promoter region (from −1338 to +24) was subcloned into pGL3 Basic using XhoI and HindIII sites. The primer set was as follows: sense 5′-CTCGAGTGTGGAAGGGGAAGGT-GAAGG-3′, antisense 5′-AAGCTTACAGAGC-AGTGCTGAGCTGTG-3′. HEK293 cells were co-transfected with the different combinations of pGL3-IL-10 promoter, C/EBPα, mutant C/EBPα S21G, and IL-32β by using Lipofectamine® 2000 reagent (Invitrogen, Carlsbad, CA). After overnight incubation, the samples were treated with 10 μM of rottlerin or 10 μM of PD98059, after which they were treated with 20 nM of PMA for a further 24 h. Luciferase assays were performed using DualLuciferase® Reporter Assay System (Promega, Madison, WI).
Chromatin immunoprecipitation (ChIP) assay
We used the commercially available ChIP assay kit (Millipore, Bedford, MA) according to the manufacturer's instructions. Briefly, U937 cells were electroporated with IL-32 siRNA or nontargeting RNA. After overnight incubation, cells were treated with PMA for 90 min. The cells were fixed with 1% formaldehyde, lysed in kit lysis buffer, and sonicated with 5 pulses for 5 s each. After centrifugation at 13,000 rpm for 20 min, the supernatants were precleared with 45 μL of protein A agarose/salmon sperm DNA (50% slurry) for 60 min. After brief centrifugation, the supernatants were mixed with 3 μg of C/EBPα antibody and maintained overnight. Sixty microliters of protein A agarose/salmon sperm DNA (50% slurry) was added to each sample, and the pulled-down DNA fragments were eluted. PCR amplification using the eluted DNA as the template was performed for 35 cycles at an annealing temperature of 61°C. The primers for PCR amplification of the IL-10 promoter were as follows: sense (from −577 to −557) 5′-CTTTGAGGATATTTAGCC-CAC-3′, antisense (from −296 to −276) 5′-GGGCTACCTCTCTT-AGAATAA -3′. Primers for Bcl-2 and lactoferrin ChIP were : Bcl-2 sense (from −395 to −375) 5ʹ-CATTCTTTTTAGCCGTGTTAC-3ʹ, antisense (from −238 to −218) 5ʹ-GATCTTTA-TTTCATGAGGCAC-3ʹ, lactoferrin sense (from −211 to −192) 5ʹ-CAGCCAGGCAGAA-CCAGGAC-3ʹ, antisense (from −23 to −4) 5ʹ-GCCACTTGCGCCTGCCCTGC-3ʹ. We measured the optical intensity of the bands by using GelQuant.NET software provided by biochemlabsolution.com. The ChIP products were also analyzed by quantitative real-time PCR by using iQ™ SYBR® GREEN Supermix (Bio-Rad, Hercules, CA). Statistical analysis Statistical analysis was performed using the unpaired two-tailed Student t-test. Differences were considered statistically significant at p< 0.05.
Results

IL-32β promotes IL-10 production in U937 cells
upon PMA stimulation. We demonstrated previously that IL-32β promoted the production of the anti-inflammatory cytokine IL-10 in myeloid cells (28). In order to verify that IL-32β is involved in IL-10 production, we knockeddown IL-32β by using siRNA in U937 cells (Fig.  1A) . Only the production of IL-10 was decreased upon PMA treatment after IL-32β silencing, whereas the levels of TNF-α and IL-8 were not changed (Fig. 1) . The ectopic introduction of IL-32β into U937 cells further increased IL-10 production (data not shown). Therefore, these data confirmed that IL-32β upregulated the production of IL-10 by PMA treatment in U937 cells.
IL-32β associates with PMA-activated PKCδ.
We localized IL-32β in U937 cells by using confocal microscopy. Under normal conditions, IL-32β was distributed in the cytosol, but it shifted to the membrane upon PMA stimulation. LPS treatment did not result in the movement of IL-32β in U937 cells (Fig. 2) . This finding suggests that IL-32β played an indirect mediatory role rather than a role as a direct transcriptional activator for IL-10 expression. Because the effect of IL-32β on IL-10 production was PMA dependent, and its membrane localization upon PMA stimulation resembled the movement of PKC, we screened the relevant PKCs by immunoprecipitation, as we had previously performed with IL-32α (7). IL-32β specifically interacted with PMAactivated PKCδ because the interaction was inhibited by PKCδ-specific inhibitor, rottlerin, but was not by a classical PKC inhibitor, Gӧ6976 (Fig. 3A, B) . Meanwhile, several studies demonstrated that PKCδ is involved in IL-10 production (29-31). Thus, we examined whether PKCδ was involved in IL-10 production in U937 cells as well. When U937 cells were treated with increasing doses of rottlerin, the production of IL-10 was decreased in a rottlerin dose-dependent manner (Fig. 3C ). The TNF-α level was also affected by rottlerin, but IL-8 was not (Figs. 3D, E) . These data suggest that IL-32β may be inter-related with PKCδ for IL-10 production.
Serine 21 of C/EBPα is phosphorylated by PKCδ in a IL-32β-involved way in U937 cells
The human promyelomonocytic U937 cells undergo monocytic differentiation by PMA stimulation. A tissue-specific transcription factor, C/EBPα, blocks 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of bipotential myeloid cells when ectopically expressed (32), and induces growth arrest by repressing proliferation genes (10). Hence, we investigated the status of C/EBPα in U937 cells. C/EBPα was expressed in U937 cells and was phosphorylated at serine 21 by PMA stimulation (Fig. 4A) . The phosphorylation of C/EBPα S21 was inhibited by the treatment of rottlerin, a PKCδ specific inhibitor, which means that C/EBPα S21 could be phosphorylated by PKCδ as well. C/EBPα S21 phosphorylation was also inhibited by PD98059, an extracellular signalregulated kinase 1/2 (ERK1/2) inhibitor, to a lesser extent than rottlerin, as consistent with the findings of a previous study (26) (Fig. 4B) . In order to further verify that PKCδ is involved in C/EBPα S21 phosphorylation, PKCδ was knocked-down with 80 % efficiency compared with GAPDH by using PKCδ-specific siRNA. As shown in Fig. 4C , phospho-C/EBPα at S21 was significantly decreased by PKCδ silencing, which means that PKCδ also involved in C/EBPα S21 phosphorylation.We then examined whether IL-32β might affect the phosphorylation of C/EBPα. When IL-32β was knocked down by siRNA, the phosphorylation of S21 of C/EBPα was not induced upon PMA treatment (Fig. 4D) , which suggest that IL-32β involved in C/EBPα S21 phosphorylation. In order to analyze the relevance of C/EBPα to IL-10 expression, we performed chromatin immunoprecipitation (ChIP) for the putative C/EBPα-binding site on IL-10 promoter after silencing of IL-32β. We observed that the binding of C/EBPα to IL-10 promoter was increased by IL-32β knock-down. However, C/EBPα binding to Bcl-2 or lactoferrin promoter was not affected by IL-32β silencing. We further verified the ChIP results by quantitative realtime PCR (Fig. 5 ). This finding implies that IL-32β suppressed C/EBPα binding to IL-10 promoter, thereby relieving the IL-10 promoter from C/EBPα repression. ERK1/2 is known to directly phosphorylate C/EBPα S21 through an FXFP-docking site. However, we speculated that PKCδ might phosphorylate C/EBPα S21 in a IL-32β-mediated way, which inhibited the binding of C/EBPα to IL-10 promoter.
IL-32β interacts with PKCδ and C/EBPα and mediates C/EBPα S21 phosphorylation
We next investigated how IL-32β mediated C/EBPα S21 phosphorylation by PKCδ. IL-32β association with PMA-activated PKCδ was shown in Fig.  3A and B. We then examined whether C/EBPα interacted with these molecules together. We cloned human C/EBPα cDNA into 6 × myc tagged expressing vector, and then performed immunoprecipitations after co-transfection of HEK293 with different combinations of IL-32β, C/EBPα, and PKCδ. IL-32β coimmunoprecipitated with C/EBPα and PKCδ, and this interaction was inhibited by rottlerin, but not by PD98059, an ERK1/2 inhibitor (Fig.  6A, B) . The interaction of C/EBPα with IL-32β was also confirmed in U937 cells. The interaction was inhibited by the treatment of rottlerin, but not by PD98059 (Fig. 6C) . We then proved that IL-32β mediated the phosphorylation of C/EBPα S21 by PKCδ. We transfected HEK293 cells with 6 × myc tagged C/EBPα with or without IL-32β, and then immunoprecipitated C/EBPα with myc antibody. C/EBPα S21 was not phosphorylated in the absence of IL-32β. The phosphorylation of S21 was inhibited by rottlerin, but the phospho-C/EBPα S21 was still detected even in the presence of a ERK1/2 inhibitor, PD98059 (Fig.  6D) , which means that PKCδ also phosphorylated C/EBPα S21 in a IL-32β-mediated way. When C/EBPα serine 21 was mutated to glycine, it was no longer phosphorylated (Fig. 6E) . However, the interaction of C/EBPα with PKCδ and IL-32β was not inhibited by the mutation of serine 21 to glycine (S21G). We reconfirmed the interaction of IL-32β with mutant C/EBPα S21G in A549 lung carcinoma cells, which means that the phosphorylation of C/EBPα S21 did not influence its association with IL-32β and PKCδ (Fig. 6F, G) . We also characterized the interaction domains of C/EBPα and IL-32β. IL-32β interacted with the full length C/EBPα (FL) as well as F2 and F4 (Fig. 7A) . F2 contains DNA binding domain and basic leucine zipper domain, and F4 contains only basic leucine zipper domain. Therefore, these data mean that IL-32β binds to basic leucine zipper regioin of C/EBPα. C/EBPα bound to N-terminal region of IL-32β (Fig. 7B) . Most isoforms of IL-32 contain the same C-terminal (D2), but the Nterminal (D1) is diverse owing to alternative splicing. Meanwhile, the two mutants of IL-32β had no effect on IL-10 production, which means that only the intact form of IL-32β is functional (data not shown). IL-32β suppressed the inhibitory effect of C/EBPα on IL-10 expression We further investigated the effect of C/EBPα on IL-10 expression using IL-10 promoter reporter assay. We observed that IL-10 promoter was not activated under C/EBPα expression without IL-32β. However, in the presence of IL-32β, the promoter was activated (Fig. 8A) . The promoter activity was inhibited by rottlerin, but not by PD98059, which means that ERK1/2 was not involved in IL-10 expression in this system. The activity of C/EBPα is repressed by the phosphorylation of S21 (26); as is consistent with this report, a mutant C/EBPα S21G, which could not be phosphorylated by PKCδ, repressed IL-10 promoter activity even under co-expression with IL-32β (Fig. 8B) . When the cells were treated with rottlerin under mutant C/EBPα S21G expression, the promoter activity was further reduced, but was not modulated by PD98059 (Fig. 8C) . These data therefore suggest that IL-32β-mediated phosphorylation of C/EBPα S21 by PKCδ suppressed the inhibitory effect of C/EBPα on IL-10 production.
Discussion
The initiation of the proinflammatory response is a prerequisite for the proper immune responses upon viral or bacterial infections. Although the proinflammatory reaction is essential, it should be resolved in order to prevent damage to the host. IL-32 has been studied for its proinflammatory function, because multiple studies have shown its association with inflammatory diseases. IL-32β is known to induce TNF-α, IL-8, IL-6, and macrophage inflammatory protein-1 alpha (MIP-1α), all of which are proinflammatory mediators. However, we showed that IL-32β induced an anti-inflammatory cytokine IL-10 in myeloid cells. In that study, we questioned the mechanism of action of IL-32β, because IL-32β protein was detected only with cellular lysates, not in the culture medium. In this study, we solved our previous question by revealing the mechanism by which IL-32β promotes IL-10 production. Recently, several studies have shown the intracellular mediatory function of IL-32 (7) (8) 33 ). We demonstrated that IL-32β mediated the phosphorylation of serine 21 on C/EBPα by PMA-activated PKCδ, which resulted in IL-10 production. Phosphorylation of C/EBPα at S21 inhibits its transcriptional activity through induction of conformational changes. The involvement of PKCδ in IL-10 production is known, but there is little evidence of the effect of C/EBPα on IL-10 production. Although a previous study showed that C/EBPα induced IL-10 production (34), the effect was synergistic with cAMP-responsive element binding protein/activating transcription factor (CREB/ATF). C/EBPα not only activates the granulopoiesis-related genes, but also represses cell cycle-related genes, which means that C/EBPα acts as a transcriptional activator as well as a transcriptional inhibitor. There are a couple of models explaining the inhibitory function of C/EBPα. C/EBPα may inhibit Sphage genes indirectly through an association with E2F, or by direct binding to E2F sites. Alternatively, C/EBPα may directly inhibit Sphage genes by binding to the C/EBP-binding site on promoters of those genes (10). On the grounds of these reports, we examined the effect of IL-32β on C/EBPα, and showed that IL-32β inhibited C/EBPα binding to IL-10 promoter by mediating S21 phosphorylation by PKCδ. However, whether the inhibition of the IL-10 gene by C/EBPα results from the binding of C/EBPα to IL-10 promoter or the interaction of other inhibitory proteins with C/EBPα located on the IL-10 promoter remains unclear. In any event, according to our results, IL-32β has an intracellular mediatory function in addition to its proinflammatory function. Figure2. PMA-dependent shift of IL-32β localization in U937 cells. Immunofluorescence staining was performed to localize the endogenous IL-32β in U937 cells. Cells were treated with 50 nM PMA or 1 μg/ml lipopolysaccharide (LPS) for 40 min. Cells were fixed, permeabilized, and labeled for nuclei with DAPI and endogenous IL-32 with FITC. Fluorescence signals were analyzed by confocal microscopy. The same amount of mock IgG (1 μg) as KU32-52 antibody was used for control. 
